WuXi XDC Interim Revenue Reaches RMB 3.7 Billion with Adjusted Net Profit Up 37.4%
Nashnova编辑部
WuXi XDC (02268) reported first-half revenue of RMB 3.701 billion, up 37% year-on-year, as the leading ADC outsourcing platform converts record new project signings into a continuing margin-expansion story.
What do the headline numbers tell us?
Revenue hit RMB 3.701 billion, up 37% year-on-year; stripping out currency swings, constant-currency growth reached 41.5%.
Adjusted net profit came in at RMB 1.027 billion, up 37.4% — but reported profit attributable to owners rose only 9.87%. This means → forex and non-recurring items dragged down the reported figure; the adjusted number better reflects the core business.
Earnings per share: RMB 0.65. Gross profit of RMB 1.371 billion grew 40.6%, outpacing revenue growth.
What is driving this growth?
The company cites three factors: the global ADC market — antibody-drug conjugates, which attach a precision "guided-missile" chemotherapy payload to an antibody — remains highly active, lifting both client and project counts.
As the leading ADC CRDMO — a one-stop outsourced partner from R&D through manufacturing — WuXi XDC is gaining market share.
Projects are advancing from early to late stage. In plain terms = the further a project moves down the pipeline, the larger the contract value — a "funnel gets richer at the bottom" business model.
How does the standalone business look without Dongyao?
Standalone revenue reached RMB 3.556 billion, up 31.7% at actual rates and 36.2% at constant currency.
Standalone gross margin improved from 36.1% to 37.6%; standalone adjusted net margin rose from 27.7% to 28.9%.
This means → margin expansion is not an artifact of consolidating Dongyao. The core business itself is becoming more profitable as scale grows and unit costs decline.
Record new signings — what comes next?
New project signings hit an all-time high during the period, driven by sustained upstream R&D activity globally.
This reflects an ADC sector still in an up-cycle — pharma companies are handing more pipeline work to the dominant outsourcing platform.
The company itself flagged the key question: whether these new signings convert into incremental revenue in subsequent periods is the critical checkpoint for growth sustainability. Put simply = signed is not yet earned — there is a lag from contract to delivery to revenue recognition.
Content is for reference only, not financial advice.